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Abstract Insulin like growth factor (IGF)-1 and IGF-2 were
assayed from human plasma via biomolecular interaction anal-
ysis mass spectrometry, utilizing antibodies as ligands for a⁄n-
ity retrieval. Detection of both targeted and non-targeted IGFs
in the mass spectra indicated possible protein complex retrieval
by the individual antibodies. A series of control experiments
eliminated the possibility of analyte cross-walking between
£ow cells, signi¢cant antibodies cross-reactivity, and direct
IGF interactions. To disrupt the putative protein complex and
release its constituent proteins, plasma samples were treated
with detergents. An SDS-treated plasma yielded IGF signals
in a di¡erent ratio than the one observed in the mass spectra
from the non-treated plasma, suggesting disruption of the pro-
tein complex, and its retrieval from non-treated plasma. Novel
truncated IGF-2 variant, missing its N-terminal Alanine, was
detected in all mass spectra.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Biomolecular interaction analysis mass
spectrometry; Surface plasmon resonance; Matrix-assisted
laser desorption/ionization time-of-£ight mass spectrometry;
IGF-1; IGF-2; Protein complex
1. Introduction
The insulin like growth factors 1 and 2 (IGF-1 and IGF-2)
are members of an important network of proteins that regu-
late metabolic, growth, and other cellular processes and activ-
ities [1]. Primarily synthesized in the liver, the IGFs circulate
in serum in a form of protein complexes, bound to IGF-bind-
ing proteins (IGFBPs). Less than 1% of the IGFs circulate in
free, unassociated form. The binding to the IGFBPs increases
the half-life of IGFs in blood, whereas the physiological role
of the free IGF has not yet been determined. Structurally,
IGF-1 and IGF-2 share 62% amino acid sequence homology,
and there is 40% homology between the IGFs and proinsulin.
Immunoassays (ELISA, radio, or chemiluminescence) are
generally used for assaying IGFs in plasma/serum. Because
the concentration of free IGFs in serum samples can increase
upon storage (due to proteases-induced release of the bound
IGFs), determination of the total IGF is preferred in clinical
research and practice. Acid ethanol extraction is commonly
used to release the bound IGFs prior to assaying, although
additional steps are often required to minimize the IGFBPs
interference [2,3]. IGFs measurements are routinely performed
using commercially available immunoassays [4], and recently
studies on large populations have yielded important correla-
tions between increased IGF concentrations and the risk of
cancer [5^7].
In this work we explore the detection of both free and
bound IGFs via biomolecular interaction analysis mass spec-
trometry (BIA/MS) [8^13]. In its core, BIA/MS is a synergy of
two individual technologies: surface plasmon resonance (SPR)
sensing [14,15] and matrix-assisted laser desorption/ionization
time-of-£ight (MALDI-TOF) MS [16,17]. Each technology
brings a unique dimension to the BIA/MS analysis : SPR is
employed for protein quanti¢cation, whereas MALDI-TOF
MS is utilized to delineate structural features of the analyzed
biomolecules. Due to the non-destructive nature of the SPR
detection, in-vivo assembled protein complexes can be ana-
lyzed in the SPR Biosensor and subsequently delineated in
the MALDI-TOF MS analysis [18]. In this work we assayed
the IGFs utilizing antibodies as ligands for a⁄nity retrieval of
the proteins in their complexed and free forms from human
plasma.
2. Materials and methods
2.1. Proteins and antibodies
A⁄nity-puri¢ed rabbit anti-human IGF-1 antibody (anti-IGF-1)
was obtained from Cell Sciences (Norwood, MA, USA). Mouse
anti-human IGF-2 antibody (anti-IGF-2), and recombinant IGF-1
and IGF-2 were purchased from US Biological (Swampscott, MA,
USA).
2.2. Samples
Human blood was obtained from a single subject recruited within
Intrinsic Bioprobes Inc. (IBI), following a procedure approved by the
IBI’s Institutional Review Board, and after signing of an Informed
Consent form. In short, 45 Wl human blood was drawn under sterile
conditions from a lancet-punctured ¢nger with heparinized microcol-
umn (Drummond Scienti¢c Co., Broomall, PA, USA), mixed with 200
Wl of HEPES bu¡ered saline (HBS-EP) bu¡er (0.01 M HEPES, pH
7.4, 0.15 M NaCl, 0.005% (v/v) polysorbate 20, 3 mM EDTA) and
centrifuged for 30 s (at 7000 rpm, 2500Ug) to pellet the red blood
cells. The supernatant (plasma) was used as is, or it was diluted ¢ve-
fold with HBS-EP bu¡er (for a ¢nal dilution of 50U)
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2.3. SPR analysis
A Biacore X instrument (Biacore AB, Uppsala, Sweden) was uti-
lized for the ¢rst dimension of BIA/MS (a⁄nity retrieval and SPR
quanti¢cation). CM5 Research Grade Sensor Chips (carboxymethyl-
dextran derivatized surface, Biacore AB) were used in the experi-
ments, with HBS-EP running bu¡er at a £ow rate of 5 Wl/min. The
proteins were immobilized on sections (£ow cells, FC) on the chip
surface following a standard EDC/NHS (N-ethyl-NP-(dimethylamino-
propyl) carbodiimide/N-hydroxysuccinimide) coupling protocol [19].
Regeneration of the protein surfaces was achieved via short injections
of 0.06 N HCl.
2.4. MALDI-TOF MS analysis
Following removal from the biosensor, chips were washed with
three 200 Wl aliquots of distilled water and prepared for MS by ap-
plication of a MALDI matrix (aqueous solution of K-cyano-4-hydrox-
ycinnamic acid, in 33% (v/v) acetonitrile, 0.2% (v/v) tri£uoroacetic
acid) with a matrix aerosol application device [20]. The MS analysis
was performed on a homemade MALDI-TOF mass spectrometer [9].
Each site/FC on the sensor chip was targeted individually with the
nitrogen laser, allowing site-speci¢c BIA/MS analysis. The mass spec-
tra were acquired in positive ion-mode.
3. Results and discussion
Following the immobilization of V111 fmol of anti-IGF-1
in FC2 and 150 fmol of anti-IGF-2 in FC1 (sensorgrams not
shown), a 50 Wl aliquot of fresh, 50-fold diluted human plas-
ma was injected over the antibody derivatized FC1 and FC2
surfaces (Fig. 1a). At the time of chip undocking from the
biosensor, responses of 250 and 164 RU (response unit) were
observed in FC1 and FC2, indicating binding of 250 and 164
pg of proteinaceous material, respectively. The mass spectra
taken from the surfaces of the two FCs after the plasma in-
jection are shown in Fig. 1b. Noticeable are signals (singly
and doubly charged ions) coming from the targeted proteins:
IGF-1 signals (MWIGF1 = 7648.7) dominate the spectrum ob-
tained from the surface of FC2 (the anti-IGF-1 derivatized
FC), whereas signals from IGF-2 (MWIGF2 = 7469.4) are ob-
served in the mass spectrum taken from the FC1 surface (the
anti-IGF-2 derivatized FC). Interestingly, smaller intensity
signals from IGF-2 in FC2, and IGF-1 in FC1, are also
present, even though they were not targeted by the corre-
sponding antibodies in these FCs. There are three possible
explanation for the observance of these signals: (1) an analyte
cross-walk occurred between the two FCs in the post-biosen-
sor manipulation (most notably, the application of the MAL-
DI matrix); (2) the immobilized antibodies exhibit cross-reac-
tivity toward the non-targeted protein (as already stated, the
IGFs share 62% sequence homology; and (3) a protein com-
plex containing both IGF-1 and IGF-2 was retrieved during
the SPR analysis.
In order to eliminate the possibility of cross-walking be-
tween the adjacent FCs, two additional CM5 chips was uti-
lized: a single FC on the ¢rst chip was derivatized with anti-
IGF-1, and one FC on the second chip was derivatized with
anti-IGF-2. A 50 Wl aliquot of fresh human plasma, diluted
10-fold, was injected over both chips in two separate experi-
ments (sensorgrams not shown), and the chips were undocked
and analyzed via MALDI-TOF MS. The resulting mass spec-
tra are shown in Fig. 2. The presence the two IGFs in both
mass spectra is clearly indicated by their corresponding sig-
nals, discounting the possibility of FC-cross-walking in the
previous experiment. Moreover, due to the better resolution
of the spectra, the signal at lower m/z from the main IGF-2
peak in the mass spectrum obtained from the anti-IGF-2 de-
rivatized FC was identi¢ed as a truncated form of IGF-2
missing its N-terminal Alanine (MW=7398.3). The spectra
also contain several other signals, two of which can be attrib-
uted to apolipoprotein C-I (ApoC-I, MW=6,630.6) and its
truncated isoform missing the N-terminal Thr^Pro residues
(ApoC-IP, MW=6432.4). ApoC-I and ApoC-IP are abundant
plasma proteins that, as we have shown previously [20,21],
Fig. 1. a: SPR sensorgrams resulting from an injection of 50-fold
diluted human plasma sample over the anti-IGF-1 and anti-IGF-2
derivatized FC surfaces. b: MALDI-TOF mass spectra taken from
the anti-IGF-1 and anti-IGF-2 derivatized FCs following the injec-
tion of the 50-fold diluted plasma sample.
Fig. 2. MALDI-TOF mass spectra taken from anti-IGF-1 and anti-
IGF-2 derivatized FCs (on separate sensor chips), following injec-
tions of 10-fold diluted plasma samples.
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bind non-speci¢cally to the chip surface. This higher level of
non-speci¢c binding was somewhat expected due to the high
concentration of plasma (10-fold) utilized in this example.
To delineate the antibodies cross-reactivity, another CM5
chip was derivatized with anti-IGF-1 and anti-IGF-2 antibod-
ies. This time, instead of plasma, pure samples of IGF-1 and
IGF-2 (recombinant, and extensively puri¢ed, s 98%, in
HBS-EP bu¡er) were injected over the surfaces at concentra-
tions of 1033, 1034 and 1035 mg/ml. The resulting sensor-
grams were baseline corrected by mathematically subtracting
bu¡er (HBS-EP) curves (obtained via injections of 50 Wl ali-
quots of HBS-EP bu¡er right before the samples injections1)
from the samples curves. Shown in Fig. 3 are the sensorgrams
resulting from the injections of 50 Wl aliquots of 1034 mg/ml
solutions of IGF-1 and IGF-2 over anti-IGF-1 and anti-IGF-
2 derivatized FCs (the normal levels of IGF-1 and IGF-2 in
plasma are V150 Wg/ml and V500 Wg/ml, respectively [22]).
The SPR responses taken 180 s after the end of the injections
indicate that the amount of cross-reactivity for each of the
antibodies was less than 5%, which can not account for the
relative ratios of the IGF-1 and IGF-2 signals observed in
Fig. 2 (similar cross-reactivities were observed for the other
two concentrations studied, results not shown). To ultimately
test the antibodies’ cross-reactivities, a 50 Wl aliquot of HBS-
EP solution containing both IGF-1 and IGF-2 (each at 1034
mg/ml) was injected over the anti-IGF-1 and anti-IGF-2 anti-
body derivatized surfaces and the chip was subjected to MAL-
DI-TOF MS. The resulting mass spectra (Fig. 4) indicate that
only IGF-1 and IGF-2 were retrieved in their corresponding
FC, without any cross-reactivities.
In another set of control experiments, recombinant IGF-1
and IGF-2 were immobilized on the sensor chip surfaces and
screened for possible interactions with each other via injec-
tions of pure IGFs samples (results not shown). As expected,
no such interaction was detected. However, the interactions of
the IGFs with IGFBPs have been extensively documented
[23^25] and it possible that the immobilized antibodies re-
trieved the entire IGF^IGFBPs complex, which, upon matrix
application, fell apart and yielded the IGF-1 and IGF-2 sig-
nals in the mass spectra. Consequently, signals from the
IGFBP should also have been observed in the mass spectra
shown in Fig. 2. However, other than several unspeci¢ed wide
peaks, and a relatively noisy baseline, signals due to speci¢c
IGFBPs could not be explicitly delineated in the higher mass
region (not shown).
In order to more substantially demonstrate the retrieval of
the protein complex, fresh human plasma was treated with
several detergents to possibly disrupt the protein complex
and release its constituent proteins. For the ¢rst sample, 20
Wl of pure plasma (undiluted) was mixed with 20 Wl of 0.5%
SDS solution, incubated 30 min at room temperature, and
further diluted with 160 Wl of HBS-EP bu¡er to yield a plasma
sample diluted 10-fold in bu¡er and 0.05% SDS. Another
sample of plasma (10-fold diluted) was prepared in HBS-EP
bu¡er containing 0.1% Tween 20. These two samples, along
with a non-treated plasma control sample (10-fold diluted in
HBS-EP) were injected in 10 Wl aliquots over anti-IGF-1 and
IGF-2 derivatized surfaces on a new CM5 sensor chip. The
Fig. 3. SPR sensorgrams showing the injections of puri¢ed solution
of recombinant IGF-1 and IGF-2 over anti-IGF-1 (a) and anti-
IGF-2 (b) derivatized FCs. The sensorgrams shown were baseline
corrected by mathematically subtracting bu¡er (HBS-EP) curves
(obtained via injections of 50 Wl aliquots of HBS-EP bu¡er right be-
fore the samples injections, not shown in the ¢gure) from the sam-
ples curves.
Fig. 4. MALDI-TOF mass spectra taken from anti-IGF-1 and anti-
IGF-2 derivatized FCs following an injection of a bu¡er solution
containing 1034 mg/ml IGF-1 and IGF-2.
1 This type of SPR signal referencing was necessary due to the con-
stant positive bulk refractive index change observed during the SPR
analysis, which was di¡erent between the two FCs, thus eliminating
the possibility for parallel FC referencing. Also, to make the SPR
readings consistent, all injections were performed exactly 60 s follow-
ing the end of the regeneration solution (0.06 M HCl) injection, and
readings taken 180 s after the end of the injections, which were per-
formed without the consequent wash.
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resulting sensorgrams are shown in Fig. 5. The injection of the
SDS-treated plasma sample resulted in SPR responses of 80
and 51 RU in FC1 and FC2, respectively (the readings were
taken 85 s after the end of the injections). These responses are
signi¢cantly lower than the responses observed from the un-
treated sample injection (288 RU in FC1 and 197 RU in
FC2), and the SPR responses observed after the injection of
the Tween-treated plasma sample (239 RU in FC1 and 246 in
FC2). The lower responses observed for the SDS-plasma sam-
ple could indicate the possible disruption of the protein com-
plex and retrieval of only IGF-1 and IGF-2 by the immobi-
lized antibodies, which would in turn yield lower SPR
responses due to the lesser amount of total protein amount
captured on the surface. In preparation for MALDI-TOF MS
analysis, another aliquot of the SDS-treated plasma sample
(50 Wl) was injected over the regenerated surface of the same
sensor chip, yielding SPR responses of 287 and 96 RU in FC1
and FC2, respectively (sensorgram not shown). The mass
spectra taken from the surface of this sensor chip are shown
in Fig. 6. The signals from the targeted proteins (IGF-1 in the
anti-IGF-1 derivatized FC, and IGF-2 and its truncated iso-
form in the anti-IGF-2 FC) dominate the spectra, with very
little presence of the other non-targeted IGF. The peak ratio
of targeted vs. non-targeted IGFs is clearly di¡erent from the
one observed in Fig. 2, providing a strong evidence that the
treatment of the plasma sample with SDS released the IGFs
from a putative protein complex. The spectra shown in Fig. 6
were much easier to obtain (with better S/N ratio and resolu-
tion) than those shown in Fig. 2, adding to the argument that
there were more components that just the targeted proteins
retrieved on the surface of the sensor chip in the experiments
leading to Fig. 2.
The experimental data shown in this work suggest that both
bound and free IGF-1 and IGF-2 from human plasma were
detected by using single antibodies but di¡erent sample prep-
aration. Several control experiments were performed to ensure
the validity of the data. Most importantly, it was established
that the antibodies do not exhibit signi¢cant cross-reactivity
toward the other, non-targeted IGF. The only possible expla-
nation for the retrieval of both IGFs from plasma under na-
tive conditions is that the proteins are joined together in a
multi-protein complex. Whereas it is a well established that
IGF-1 and -2 do not interact with each other (which was also
veri¢ed in a control experiment in this study), it is known that
most of the circulating IGF-1 and IGF-2 are complexed to
IGFBPs. For this reason, we postulate that the entire IGF^
IGFBP protein complex was retrieved by the antibodies under
native conditions, yielding signals from both IGFs in the mass
spectra. The absence of signals from IGFBPs in the mass
spectra might be attributed to signal suppression e¡ects,
which often occur when one protein yields strong signals in
the mass spectrum so that signals of other proteins present in
the sample are suppressed and, consequently, not observed.
Small proteins (such as the IGFs) are known to ionize readily
and much easier than higher MW proteins (such as the
IGFBP3, the major IGFBP, with three possible glycosylation
sites), yielding to suppression of the higher MW signals.
In summary, ligands with a⁄nities toward a protein that is
part of in-vivo assembled complexes can be used as ‘hooks’ to
retrieve the entire protein complex from a biological sample
prepared under native (non-denaturing) conditions. In BIA/
MS, the SPR sensing o¡ers a unique opportunity to monitor
the state of these protein complexes as a function of solvent
variations, whereas the subsequent MALDI-TOF MS analysis
of the retained components yields signals that reveal the
masses of the constituent proteins, along with any structural
modi¢cations present. Given the dual aspect of the analysis
(quantitative and qualitative), BIA/MS holds great promise in
investigating protein complexes and the mechanisms behind
their assembly.
Fig. 5. SPR sensorgrams resulting from injections of 10-fold diluted
pure, Tween-treated, and SDS-treated plasma samples, over anti-
IGF-1 (a) and anti-IGF-2 (b) derivatized FCs.
Fig. 6. MALDI-TOF mass spectra taken from the anti-IGF-1 and
anti-IGF-2 derivatized FC surfaces following the injection of the
SDS-treated plasma sample.
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